Nxera Pharma Co (4565.T) Stock Price
Nxera Pharma Co Price
Over the last 19 years Nxera Pharma Co grew revenue by 21.4% annually, reaching 29.62 B JPY. Earnings per share have declined at 13.5% per year over the last 10 years. For Nxera Pharma Co, the net margin of -42.3% is down versus 5.7% a few years ago. At today's price the dividend yield works out to roughly 0.18%. The consensus 12-month price target for Nxera Pharma Co is 1,224.00 JPY, about 13.1% below where the stock trades today. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.
Nxera Pharma Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Nxera Pharma Co business model & stock analysis
Frequently asked questions about Nxera Pharma Co
The business model of Sosei Group Corp. focuses on discovering, developing, and commercializing innovative medicines. Sosei Group Corp. operates through two primary business segments: “Discovery and Early Development” and “Late-stage Development and Commercialization”. The company collaborates with global partners to research and create novel drugs and therapies addressing unmet medical needs in various therapeutic areas, including respiratory, neurology, and oncology. Sosei Group Corp. aims to leverage its proprietary technologies and expertise in drug discovery and development to deliver life-changing treatments to patients worldwide.
Sosei Group Corp is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Sosei Group Corp in the market include multinational pharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies are also engaged in the research, development, and commercialization of innovative drugs and therapies. However, Sosei Group Corp stands out in the market due to its unique focus on drug discovery and development, utilizing its proprietary platform technologies. As a global biopharmaceutical company, Sosei Group Corp strives to differentiate itself and expand its product portfolio in its pursuit of breakthrough treatments and therapies.
Sosei Group Corp. is a renowned pharmaceutical company with a rich history and profound background. Founded in 1990, Sosei Group Corp. is headquartered in Tokyo, Japan. The company focuses on discovering, developing, and commercializing innovative medicines for various therapeutic areas. Sosei Group Corp. has a strong track record of successfully bringing novel drugs to market, addressing significant medical needs worldwide. With a team of experienced researchers and development experts, the company emphasizes cutting-edge technologies and collaborations to drive its discoveries. Sosei Group Corp. is committed to improving patients' lives through its groundbreaking pharmaceutical solutions while continuously expanding its global presence.
Some significant milestones achieved by Sosei Group Corp include the successful completion of clinical trials for multiple novel therapeutic candidates, such as R-pasudotox, NVA237, and QVA149. The company also entered into strategic alliances and partnerships with major pharmaceutical companies, allowing for the development and commercialization of its products on a global scale. Furthermore, Sosei Group Corp successfully launched its first proprietary product, SOF-021, for chronic obstructive pulmonary disease (COPD) in Japan. These milestones demonstrate the company's commitment to innovation and market expansion, solidifying its position as a leading player in the biopharmaceutical industry.
Sosei Group Corp is primarily present in Japan and the United Kingdom.
Sosei Group Corp represents values of innovation, collaboration, and global expansion. With a commitment to creating groundbreaking pharmaceuticals, the company focuses on leveraging their proprietary drug discovery platforms to develop novel treatments for unmet medical needs. Sosei Group Corp strives to foster partnerships with other industry leaders to enhance research and development capabilities and accelerate the delivery of life-changing therapeutics to patients worldwide. Emphasizing patient-centricity, Sosei Group Corp aims to improve healthcare and contribute to society through its cutting-edge technologies and commitment to scientific excellence.
Analysts currently set an average price target of 1,390.11 JPY for the Nxera Pharma Co stock (median: 1,224.00 JPY), implying -1.3 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Nxera Pharma Co stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Nxera Pharma Co to generate revenue of 40.59 B JPY and earnings per share of 46.63 JPY.
Converted at the current exchange rate, the Nxera Pharma Co share trades at 7.99 EUR (1,409.00 JPY).
The Nxera Pharma Co share (4565.T) is listed on 4 stock exchanges, including: Tokio (JPX) (4565.T), Frankfurt (JSS.F), München (JSS.MU).
The Sosei Group Corp is an innovative Japanese biopharmaceutical company that focuses on the discovery and development of new drugs. The company's business model consists of three main divisions: Sosei Heptares, Sosei NCE, and Sosei CMC. Sosei Heptares is the leading platform for the discovery and development of drugs targeting G-protein-coupled receptors (GPCRs). These receptors are an important target for a variety of diseases. Sosei Heptares has a robust pipeline with multiple clinical candidates in various therapeutic areas such as immunology, metabolism, neurology, and oncology. Key products of Sosei Heptares include the recently approved drugs Seebri Breezhaler and Utibron Neohaler for the treatment of COPD (chronic obstructive pulmonary disease). Sosei NCE focuses on the discovery and development of new drugs with innovative mechanisms of action and high therapeutic efficacy. The company is currently developing drugs for the treatment of non-infectious diseases such as cancer, inflammation, and metabolic disorders. A key product of Sosei NCE is the clinical candidate Oligo-controlled release (OCR) for the treatment of type 2 diabetes. Sosei CMC is the company's center of excellence for the chemical manufacturing of drugs. Sosei CMC offers a wide range of services, including process development, scale-up, and GMP production of NCEs, biological drugs, and inhalation products. The company has extensive experience in manufacturing drugs for clinical trials and commercial production. The business model of Sosei Group Corp is based on an integrated platform technology strategy. The company leverages its extensive expertise in GPCR research to discover innovative drug candidates that are further developed by its NCE and CMC divisions. Sosei Group Corp has entered into a number of partnerships with leading pharmaceutical companies such as AstraZeneca, Novartis, and Pfizer to accelerate the development and commercialization of its products. The company also aims to have a strong presence in the Japanese market and collaborates closely with Japanese companies such as Takeda Pharmaceutical, Ono Pharmaceutical, and Astellas Pharma. In addition, Sosei Group Corp has built a global presence by establishing branches and subsidiaries in North America, Europe, and Asia. In summary, Sosei Group Corp develops and markets innovative drug candidates through its integrated platform technology strategy, aiming to improve healthcare worldwide. The various divisions focusing on drug discovery, development, and chemical manufacturing form the foundation of this business model.
The expected revenue of Nxera Pharma Co is 40.59 B JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Nxera Pharma Co is 4.21 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Nxera Pharma Co is currently 30.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nxera Pharma Co stock.
The price-to-sales ratio (P/S) of Nxera Pharma Co is currently 3.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nxera Pharma Co stock.
The Eulerpool Quality Score for Nxera Pharma Co is 4/10.
The ISIN of Nxera Pharma Co is JP3431300007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Nxera Pharma Co is A0B7EK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Nxera Pharma Co is 4565.T. The ticker symbol is used to trade Nxera Pharma Co shares on the stock exchange.
Nxera Pharma Co stock
Nxera Pharma Co Peer Group
Nxera Pharma Co Ticker
Nxera Pharma Co FIGI
All fundamentals and in-depth analysis of Nxera Pharma Co
Our stock analysis for Nxera Pharma Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.